Albuterol in Patients With Lymphangioleiomyomatosis
Doctors at the National Institutes of Health (NIH) are enrolling people with LAM into a research study. LAM is a rare progressive lung disease that usually strikes women during their childbearing years, between the onset of puberty and menopause. One possible treatment to improve breathing in patients with LAM is inhaled albuterol. Albuterol can be given using a hand held inhaler or with a nebulizer. The study wants to compare these methods to see which method improves lung function in patients with LAM.
About the Study
- Participants will have a physical exam and medical history
- 3-day overnight stay our hospital (NIH Clinical Center)
- Participants will take albuterol using a hand held inhaler and nebulizer during their hospital stay
Who can participate?
- Adult women who have impaired lung function because of LAM
- With no known allergy to albuterol
The NIH Clinical Center, America's Research Hospital, is located on the Metro red line (Medical center stop) in Bethesda, Maryland. There is no charge for study-related tests, medications or procedures. Travel assistance may be provided. Parking is available.
For more information:
NIH Clinical Center
Office of Patient Recruitment
1-800-411-1222 (refer to study # 13-H-0051)
TTY for the deaf or hard of hearing: 1-866-411-1010
Se habla español
Or go online:
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung, and Blood Institute (NHLBI)
Print the Flyer
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 06/28/2019